Initial Dose of Three Monthly Intravitreal Injections versus PRN Intravitreal Injections of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

Table 1

Patient demographics and baseline ocular characteristics in the PRN and 3 monthly initial dose groups.

	PRN group (𝑛=69)	Three monthly initial dose group (𝑛=26)	𝑃
Age	61.9±12.3	60.0±8.4	0.46
Sex: male, female	32 : 37	13 : 13	0.75
Diabetes mellitus (%)	4 (5.8%)	4 (15.4%)	0.21
Hypertension (%)	30 (43.5%)	11 (42.3%)	0.92
Location of retinal vein occlusion,; ST BRVO : IT BRVO	40 : 29	18 : 8	0.32
Pretreatment visual acuity, log MAR	0.61±0.35; (range: 0.22–1.7)	0.65±0.34; (range: 0.22–1.4)	0.61
Ischemic* BRVO: non-ischemic BRVO	38 : 31	16 : 10	0.57
OCT findings
Pretreatment central retinal thickness, 𝜇m	510±150	528±124	0.58
Photoreceptor IS-OS status,; Normal : disrupted (%)	21 : 48; (30.4% : 69.6%)	8 : 18; (30.8% : 69.2%)	1.0
Photoreceptor ELM status,; Normal : disrupted (%)	37 : 32; (53.6% : 46.4%)	14 : 12; (53.8% : 46.2%)	1.0
Serous macular detachment (%)	34 (49.3%)	14 (53.8%)	0.69
Funduscopic and angiographic findings
Foveal nonperfusion (%)^†	16 (23.2%)	5 (19.2%)	0.68
Area of retinal hemorrhage, %^‡	16.0±12.7	21.1±14.1	0.10
Area of capillary nonperfusion, %^‡	29.8±13.6	28.7±17.1	0.76

BRVO: branch retinal vein occlusion; ELM: external limiting membrane; IS-OS: inner segment-outer segment; IT: inferior temporal; ST: superior temporal.
𝑃 value was obtained by student’s 𝑡-test for continuous variables and chi-square or Fisher’s exact test for dichotomous variables.
*Nonperfused area divided by the optic disc area ≥5.
^†Foveal nonperfusion was defined as the extent of capillary dropout on the fovea for >1 quadrant.
^‡The area of retinal hemorrhage or capillary nonperfusion was measured in a circle with a radius of 3600 𝜇m centred on the fovea using Image𝐽 software. By dividing this area by the area of the circle with a radius of 3600 𝜇m, the percentage of the area of retinal hemorrhage or capillary nonperfusion was calculated.